注册
忘记密码
忘记用户名
专家账号密码找回2型炎症反应是由Th2、2型固有淋巴样细胞和Th2型细胞因子共同驱动的炎症过程。Th2型细胞因子包括主要由免疫细胞分泌的白细胞介素（IL）⁃4、IL⁃5、IL⁃9、IL⁃13和IL⁃31，以及主要由组织细胞特别是上皮细胞分泌的IL⁃25、IL⁃33和胸腺基质淋巴细胞生成素。随着对2型炎症反应发病机制的不断探索，发现异常2型炎症反应参与了多种以慢性组织炎症为特征的皮肤疾病。近年来，抑制2型炎症反应的治疗策略不断更新，包括靶向细胞因子或其受体的生物制剂，以及阻断细胞内细胞因子信号通路的Janus激酶抑制剂。本文对2型炎症性皮肤病在发病机制和治疗策略方面的进展进行总结。
当前位置：首页 / 2型炎症性皮肤病的发病机制和治疗进展
|
更新时间：2025-07-01
|
2型炎症性皮肤病的发病机制和治疗进展
Pathogenesis and treatment progress on type 2 inflammatory skin disease
广西医学 页码：651-658
作者机构：李秋菊，博士，主治医师，研究方向为银屑病、特应性皮炎等炎症性皮肤病。
基金信息：广西自然科学青年科学基金（区域高发疾病研究联合专项）（2024GXNSFBA010069）
- 中文简介
- 英文简介
- 参考文献
Type 2 inflammatory response is an inflammatory process driven by the combined action of Th2, type 2 innate lymphoid cell, and type Th2 cytokines. Type Th2 cytokines include interleukin (IL)⁃4, IL⁃5, IL⁃9, IL⁃13, and IL⁃31, primarily secreted by immune cells, as well as IL⁃25, IL⁃33, and thymic stromal lymphopoietin, mainly produced by tissue cells, particularly epithelial cells. With ongoing research into the pathogenesis of type 2 inflammatory response, it has been implicated that abnormal type 2 inflammatory response participated in various skin diseases characterized by chronic tissue inflammation. In recent years, treatment strategies of inhibiting type 2 inflammatory response have continued to evolve, including biologics of target cytokines or their receptors, as well as Janus kinase inhibitors of blocking intracellular cytokine signaling pathways. This paper summarizes progress on the pathogenesis and treatment strategies of type 2 inflammatory skin diseases.
-
无
下载
收藏
